Webinar Journey to Titer-scale Car-T cell production with perfusion

On-Demand Webinar | The Journey to Liter-Scale CAR-T Cell Production with Perfusion

Reducing the cost per dose of allogeneic CAR-T therapies requires scalable solutions that enable mass production.

In this webinar with experts from UCL and Repligen, we showcase the scale-up of a CAR-T perfusion process in single-use stirred-tank bioreactors with automated cell harvesting and serum-free, xeno-free medium. Join and learn strategies to seamlessly scale up CAR-T expansion for allogenic applications.

What You Will Learn:

Expanding CAR-T cells in 2 L single-use stirred-tank bioreactors coupled with ATF perfusion.
The benefits of using xeno-free medium in CAR-T expansion. 
The impact of automated bioreactor harvesting and buffer exchange on CAR-T cell quality.

Clear form data

Please Complete the Form

First Name *

Last Name *

E-Mail *

Phone Number *

Company *

Job Title *

Address *

Country *

Postal Code *

I would like to sign up for newsletters from Sartorius (Sartorius AG and its affiliated companies) based of my personal interests.
I can revoke my consent at any time with effect for the future by sending an e-mail to unsubscribe@sartorius.com or by clicking on the "unsubscribe" link in e-mails I have received.

* These fields are required Information on the use of your data can be found in our privacy policy

Complete Form to Watch

Pierre Springuel

PhD Candidate, University College London

Pierre Springuel is a PhD candidate in the Department of Biochemical Engineering at University College London. His research focuses on developing and optimizing scalable manufacturing processes to enable large-scale production of CAR-T cell therapies. He specializes in perfusion process intensification and scale-up in stirred-tank bioreactors, and in automating downstream processing.  

Earl Pineda

Associate Director of Upstream Field Applications, Repligen Corporation

Earl Pineda is the associate director of upstream field applications at Repligen. Earl has been in the biotech industry for about 25 years, and has helped hundreds of companies successfully implement XCell^® ATF technology globally over the past 14 years.  He has worked at major biotech companies like Amgen, Novartis and Biomarin in process development, MSAT, and technology transfer.  

Dr. Qasim Rafiq

Professor of Cell and Gene Therapy Bioprocess Engineering, Vice Dean (Health) in Faculty of Engineering at UCL

Dr. Qasim Rafiq is Vice Dean for Health in the Faculty of Engineering and a Professor in Bioprocess Engineering at University College London. He is a multidisciplinary engineer focusing on the bioprocessing, automation, and biomanufacturing of cell and gene-based therapies. 

Julia Hengst

Product Manager, Immune Cell Media

Julia Hengst is Product Manager for Immune Cell Media at Sartorius. She joined the company as an External Collaborations Manager, where she built and led partnerships through scientific collaborations around immune and stem cell therapies. 

She holds a PhD in immunology and has years of experience in product management for biomedical research and cell and gene therapy clinical applications.